Is Avadel Pharmaceuticals PLC (AVDL) Stock About to Get Hot Tuesday?

The market has been down on Avadel Pharmaceuticals PLC (AVDL) stock recently. AVDL gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Avadel Pharmaceuticals PLC has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AVDL!

See Full AVDL Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With AVDL Stock Today?

Avadel Pharmaceuticals PLC (AVDL) stock is trading at $15.79 as of 12:43 PM on Tuesday, Mar 19, a gain of $0.02, or 0.13% from the previous closing price of $15.77. The stock has traded between $15.62 and $15.98 so far today. Volume today is less active than usual. So far 128,976 shares have traded compared to average volume of 1,572,164 shares.

More About Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States. Click Here to get the full Stock Report for Avadel Pharmaceuticals PLC stock.